{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:31Z","timestamp":1792783351569,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["50461-2025"],"award-info":[{"award-number":["50461-2025"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Research Foundation of Korea","award":["RS-2021-NR056276"],"award-info":[{"award-number":["RS-2021-NR056276"]}],"id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Research Foundation of Korea","award":["RS-2022-NR072455"],"award-info":[{"award-number":["RS-2022-NR072455"]}],"id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate-specific membrane antigen (PSMA) has emerged as a clinically validated target for the diagnosis and treatment of prostate cancer using radioligand therapy (RLT). Among various PSMA-targeting ligands, urea-based small-molecules have gained limelight due to their favorable pharmacokinetic properties, high tumor penetration and convenient radiolabeling. Current preclinical research focuses on enhancing in vivo efficacy by optimizing ligand design, radionuclide selection, and improved pharmacokinetics. To reduce off-target toxicity in organs and enhance tumor accumulation, strategies involving the incorporation of albumin-binding moieties or linker modifications have been explored. Various studies have focused on PSMA-targeted therapies labeled with radionuclides, including \u03b2 emitters (lutetium-177), \u03b1 emitters (actinium-225 or astatine-211), and Auger electron emitters (iodine-125), that provide unique DNA damage mechanisms tailored to the tumor size and disease stage. This review summarizes recent approaches of PSMA-targeted small-molecules to optimize therapeutic efficacy while minimizing adverse effects on healthy tissues for RLT of prostate cancer.<\/jats:p>","DOI":"10.1007\/s13139-025-00979-1","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T01:37:10Z","timestamp":1769391430000},"page":"204-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Current Status of PSMA-Targeted Agents Based on Small Molecules for Prostate Cancer in Preclinical Studies"],"prefix":"10.1007","volume":"60","author":[{"given":"Ayman","family":"Muzammal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyo Chul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5794-3280","authenticated-orcid":false,"given":"Sairan","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"979_CR1","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA, et al. The Lancet commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403:1683\u2013722.","journal-title":"Lancet"},{"key":"979_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"979_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40164-023-00444-9","volume":"12","author":"GL Varaprasad","year":"2023","unstructured":"Varaprasad GL, Gupta VK, Prasad K, Kim E, Tej MB, Mohanty P, et al. Recent advances and future perspectives in the therapeutics of prostate cancer. Exp Hematol Oncol. 2023;12:80.","journal-title":"Exp Hematol Oncol"},{"key":"979_CR4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/bs.acr.2024.07.004","volume":"164","author":"J Zhong","year":"2024","unstructured":"Zhong J, Jang A, Garcia J, Avril N, Li Q, Wojtylak P, et al. Advances in prostate cancer treatment: radionuclide therapy for prostate cancer. Adv Cancer Res. 2024;164:311\u201358.","journal-title":"Adv Cancer Res"},{"key":"979_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701\u201311.","journal-title":"Nat Rev Cancer"},{"key":"979_CR6","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1038\/onc.2013.206","volume":"32","author":"T Karantanos","year":"2013","unstructured":"Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32:5501\u201311.","journal-title":"Oncogene"},{"key":"979_CR7","doi-asserted-by":"crossref","first-page":"175883592311576","DOI":"10.1177\/17588359231157632","volume":"15","author":"A Jang","year":"2023","unstructured":"Jang A, Kendi AT, Sartor O. Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials. Ther Adv Med Oncol. 2023;15:17588359231157632.","journal-title":"Ther Adv Med Oncol"},{"key":"979_CR8","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s00262-006-0131-0","volume":"55","author":"P Wolf","year":"2006","unstructured":"Wolf P, Gierschner D, B\u00fchler P, Wetterauer U, Els\u00e4sser-Beile U. A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells. Cancer Immunol Immunother. 2006;55:1367\u201373.","journal-title":"Cancer Immunol Immunother"},{"key":"979_CR9","first-page":"6357","volume":"9","author":"JS Ross","year":"2003","unstructured":"Ross JS, Sheehan CE, Fisher HAG, Kaufman RP Jr, Kaur P, Gray K, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357\u201362.","journal-title":"Clin Cancer Res"},{"key":"979_CR10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.nucmedbio.2021.04.003","volume":"98\u20139","author":"N Heynickx","year":"2021","unstructured":"Heynickx N, Herrmann K, Vermeulen K, Baatout S, Aerts A. The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: a review of the lessons learnt so far. Nucl Med Biol. 2021;98\u20139:30\u20139.","journal-title":"Nucl Med Biol"},{"key":"979_CR11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40336-019-00348-x","volume":"7","author":"F Ceci","year":"2019","unstructured":"Ceci F, Fanti S. PSMA-PET\/CT imaging in prostate cancer: why and when. Clin Transl Imaging. 2019;7:377\u20139.","journal-title":"Clin Transl Imaging"},{"key":"979_CR12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/pros.23642","volume":"78","author":"AK Miyahira","year":"2018","unstructured":"Miyahira AK, Pienta KJ, Morris MJ, Bander NH, Baum RP, Fendler WP, et al. Meeting report from the prostate cancer foundation PSMA-directed radionuclide scientific working group. Prostate. 2018;78:775\u201389.","journal-title":"Prostate"},{"key":"979_CR13","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/14737159.2016.1243057","volume":"16","author":"M Barrio","year":"2016","unstructured":"Barrio M, Fendler WP, Czernin J, Herrmann K. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer. Expert Rev Mol Diagn. 2016;16:1177\u201388.","journal-title":"Expert Rev Mol Diagn"},{"key":"979_CR14","doi-asserted-by":"crossref","first-page":"67S","DOI":"10.2967\/jnumed.116.186767","volume":"58","author":"M Eiber","year":"2017","unstructured":"Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, et al. Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med. 2017;58:67S-76S.","journal-title":"J Nucl Med"},{"key":"979_CR15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26146751","volume":"26","author":"M Neagu","year":"2025","unstructured":"Neagu M, Constantin C, Hinescu ME, Bleotu PG, Popovici M-G, Zai M-I, et al. Radionuclides landscape in prostate cancer theranostics. Int J Mol Sci. 2025;26:6751.","journal-title":"Int J Mol Sci"},{"key":"979_CR16","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.3390\/cancers13163967","volume":"13","author":"M El Fakiri","year":"2021","unstructured":"El Fakiri M, Geis NM, Ayada N, Eder M, Eder A-C. PSMA-targeting radiopharmaceuticals for prostate cancer therapy: recent developments and future perspectives. Cancers. 2021;13:3967.","journal-title":"Cancers"},{"key":"979_CR17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11864-025-01317-5","volume":"26","author":"A Ayzman","year":"2025","unstructured":"Ayzman A, Pachynski RK, Reimers MA. PSMA-based therapies and novel therapies in advanced prostate cancer: the now and the future. Curr Treat Options Oncol. 2025;26:375\u201384.","journal-title":"Curr Treat Options Oncol"},{"key":"979_CR18","doi-asserted-by":"crossref","first-page":"175883592311822","DOI":"10.1177\/17588359231182293","volume":"15","author":"M Uemura","year":"2023","unstructured":"Uemura M, Watabe T, Hoshi S, Tanji R, Yaginuma K, Kojima Y. The current status of prostate cancer treatment and PSMA theranostics. Ther Adv Med Oncol. 2023;15:17588359231182292.","journal-title":"Ther Adv Med Oncol"},{"key":"979_CR19","volume":"205","author":"JR Puik","year":"2025","unstructured":"Puik JR, Le C, Kazemier G, Oprea-Lager DE, Swijnenburg R-J, Giovannetti E, et al. Prostate-specific membrane antigen as target for vasculature-directed therapeutic strategies in solid tumors. Crit Rev Oncol Hematol. 2025;205:104556.","journal-title":"Crit Rev Oncol Hematol"},{"key":"979_CR20","volume":"7","author":"Y He","year":"2022","unstructured":"He Y, Xu W, Xiao Y-T, Huang H, Gu D, Ren S. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Ther. 2022;7:198.","journal-title":"Signal Transduct Target Ther"},{"key":"979_CR21","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.3390\/cancers15184537","volume":"15","author":"M Abusalem","year":"2023","unstructured":"Abusalem M, Martiniova L, Soebianto S, DePalatis L, Ravizzini G. Current status of radiolabeled monoclonal antibodies targeting PSMA for imaging and therapy. Cancers. 2023;15:4537.","journal-title":"Cancers"},{"key":"979_CR22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/ph12010002","volume":"12","author":"U Khalid","year":"2018","unstructured":"Khalid U, Vi C, Henri J, Macdonald J, Eu P, Mandarano G, et al. Radiolabelled aptamers for theranostic treatment of cancer. Pharmaceuticals. 2018;12:2.","journal-title":"Pharmaceuticals"},{"key":"979_CR23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2967\/jnumed.117.191874","volume":"59","author":"NM Donin","year":"2018","unstructured":"Donin NM, Reiter RE. Why targeting PSMA is a game changer in the management of prostate cancer. J Nucl Med. 2018;59:177\u201382.","journal-title":"J Nucl Med"},{"key":"979_CR24","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.7150\/thno.92612","volume":"14","author":"M Sallam","year":"2024","unstructured":"Sallam M, Nguyen N-T, Sainsbury F, Kimizuka N, Muyldermans S, Bene\u0161ov\u00e1-Sch\u00e4fer M. PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future? Theranostics. 2024;14:3043\u201379.","journal-title":"Theranostics"},{"key":"979_CR25","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00259-019-04548-5","volume":"47","author":"F Haupt","year":"2020","unstructured":"Haupt F, Dijkstra L, Alberts I, Sachpekidis C, Fech V, Boxler S, et al. 68Ga-PSMA-11 PET\/CT in patients with recurrent prostate cancer-a modified protocol compared with the common protocol. Eur J Nucl Med Mol Imaging. 2020;47:624\u201331.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"979_CR26","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2967\/jnumed.115.154336","volume":"56","author":"SP Rowe","year":"2015","unstructured":"Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, et al. 1\u2078F-DCFBC PET\/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med. 2015;56:1003\u201310.","journal-title":"J Nucl Med"},{"key":"979_CR27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11307-016-0957-6","volume":"18","author":"SP Rowe","year":"2016","unstructured":"Rowe SP, Macura KJ, Mena E, Blackford AL, Nadal R, Antonarakis ES, et al. PSMA-based [18F]DCFPyL PET\/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol Imaging Biol. 2016;18:411\u20139.","journal-title":"Mol Imaging Biol"},{"key":"979_CR28","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2967\/jnumed.112.111203","volume":"54","author":"JA Barrett","year":"2013","unstructured":"Barrett JA, Coleman RE, Goldsmith SJ, Vallabhajosula S, Petry NA, Cho S, et al. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med. 2013;54:380\u20137.","journal-title":"J Nucl Med"},{"key":"979_CR29","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3390\/molecules22040523","volume":"22","author":"E Gourni","year":"2017","unstructured":"Gourni E, Henriksen G. Metal-based PSMA radioligands. Molecules. 2017;22:523.","journal-title":"Molecules"},{"key":"979_CR30","volume":"23","author":"S Debnath","year":"2022","unstructured":"Debnath S, Zhou N, McLaughlin M, Rice S, Pillai AK, Hao G, et al. PSMA-targeting imaging and theranostic agents-current status and future perspective. Int J Mol Sci. 2022;23:1158.","journal-title":"Int J Mol Sci"},{"key":"979_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40336-019-00326-3","volume":"7","author":"SM Okarvi","year":"2019","unstructured":"Okarvi SM. Recent developments of prostate-specific membrane antigen (PSMA)-specific radiopharmaceuticals for precise imaging and therapy of prostate cancer: an overview. Clin Transl Imaging. 2019;7:189\u2013208.","journal-title":"Clin Transl Imaging"},{"key":"979_CR32","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","volume":"56","author":"M Bene\u0161ov\u00e1","year":"2015","unstructured":"Bene\u0161ov\u00e1 M, Sch\u00e4fer M, Bauder-W\u00fcst U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914\u201320.","journal-title":"J Nucl Med"},{"key":"979_CR33","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2967\/jnumed.120.248443","volume":"62","author":"A-C Eder","year":"2021","unstructured":"Eder A-C, Sch\u00e4fer M, Schmidt J, Bauder-W\u00fcst U, Roscher M, Leotta K, et al. Rational linker design to accelerate excretion and reduce background uptake of peptidomimetic PSMA-targeting hybrid molecules. J Nucl Med. 2021;62:1461\u20137.","journal-title":"J Nucl Med"},{"key":"979_CR34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26146968","volume":"26","author":"G Ferro-Flores","year":"2025","unstructured":"Ferro-Flores G, Azor\u00edn-Vega E, Ocampo-Garc\u00eda B, Luna-Guti\u00e9rrez M, Cruz-Nova P, Mel\u00e9ndez-Alafort L. Effects of targeted radionuclide therapy on cancer cells beyond the ablative radiation dose. Int J Mol Sci. 2025;26:6968.","journal-title":"Int J Mol Sci"},{"key":"979_CR35","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.3390\/molecules27165231","volume":"27","author":"S Salih","year":"2022","unstructured":"Salih S, Alkatheeri A, Alomaim W, Elliyanti A. Radiopharmaceutical treatments for cancer therapy, radionuclides characteristics, applications, and challenges. Molecules. 2022;27:5231.","journal-title":"Molecules"},{"key":"979_CR36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s12032-021-01537-3","volume":"38","author":"M Parsi","year":"2021","unstructured":"Parsi M, Desai MH, Desai D, Singhal S, Khandwala PM, Potdar RR. PSMA: a game changer in the diagnosis and treatment of advanced prostate cancer. Med Oncol. 2021;38:89.","journal-title":"Med Oncol"},{"key":"979_CR37","volume":"13","author":"BJB Nelson","year":"2021","unstructured":"Nelson BJB, Andersson JD, Wuest F. Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications. Pharmaceutics. 2021;13:49.","journal-title":"Pharmaceutics"},{"key":"979_CR38","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s11912-023-01458-6","volume":"25","author":"D Arbuznikova","year":"2023","unstructured":"Arbuznikova D, Eder M, Grosu AL, Meyer PT, Gratzke C, Zamboglou C, et al. Towards improving the efficacy of PSMA-targeting radionuclide therapy for late-stage prostate cancer-combination strategies. Curr Oncol Rep. 2023;25:1363\u201374.","journal-title":"Curr Oncol Rep"},{"key":"979_CR39","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00259-021-05434-9","volume":"49","author":"MM Sathekge","year":"2021","unstructured":"Sathekge MM, Bruchertseifer F, Vorster M, Morgenstern A, Lawal IO. Global experience with PSMA-based alpha therapy in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;49:30\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"979_CR40","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3390\/molecules30061296","volume":"30","author":"S Lacerda","year":"2025","unstructured":"Lacerda S, de Kruijff RM, Djanashvili K. The advancement of targeted alpha therapy and the role of click chemistry therein. Molecules. 2025;30:1296.","journal-title":"Molecules"},{"key":"979_CR41","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3390\/molecules25071743","volume":"25","author":"M Czerwi\u0144ska","year":"2020","unstructured":"Czerwi\u0144ska M, Bilewicz A, Kruszewski M, Wegierek-Ciuk A, Lankoff A. Targeted radionuclide therapy of prostate cancer-from basic research to clinical perspectives. Molecules. 2020;25:1743.","journal-title":"Molecules"},{"key":"979_CR42","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1021\/acs.molpharmaceut.8b00720","volume":"15","author":"H-T Kuo","year":"2018","unstructured":"Kuo H-T, Merkens H, Zhang Z, Uribe CF, Lau J, Zhang C, et al. Enhancing treatment efficacy of 177Lu-PSMA-617 with the conjugation of an albumin-binding motif: preclinical dosimetry and endoradiotherapy studies. Mol Pharm. 2018;15:5183\u201391.","journal-title":"Mol Pharm"},{"key":"979_CR43","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2967\/jnumed.120.250738","volume":"62","author":"HT Kuo","year":"2021","unstructured":"Kuo HT, Lin KS, Zhang Z, Uribe CF, Merkens H, Zhang C, et al. 177Lu-labeled albumin-binder-conjugated PSMA-targeting agents with extremely high tumor uptake and enhanced tumor-to-kidney absorbed dose ratio. J Nucl Med. 2021;62:521\u20137.","journal-title":"J Nucl Med"},{"key":"979_CR44","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1021\/acs.molpharmaceut.7b00877","volume":"15","author":"M Bene\u0161ov\u00e1","year":"2018","unstructured":"Bene\u0161ov\u00e1 M, Umbricht CA, Schibli R, M\u00fcller C. Albumin-binding PSMA ligands: optimization of the tissue distribution profile. Mol Pharm. 2018;15:934\u201346.","journal-title":"Mol Pharm"},{"key":"979_CR45","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1021\/acs.molpharmaceut.8b00152","volume":"15","author":"CA Umbricht","year":"2018","unstructured":"Umbricht CA, Benesova M, Schibli R, M\u00fcller C. Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy. Mol Pharm. 2018;15:2297\u2013306.","journal-title":"Mol Pharm"},{"key":"979_CR46","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s00259-018-4004-5","volume":"45","author":"J Kelly","year":"2018","unstructured":"Kelly J, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C Jr, Schlyer D, et al. Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors. Eur J Nucl Med Mol Imaging. 2018;45:1841\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"979_CR47","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2967\/jnumed.118.221150","volume":"60","author":"JM Kelly","year":"2019","unstructured":"Kelly JM, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C, DiMagno SG, et al. Albumin-binding PSMA ligands: implications for expanding the therapeutic window. J Nucl Med. 2019;60:656\u201363.","journal-title":"J Nucl Med"},{"key":"979_CR48","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.2967\/jnumed.116.188722","volume":"58","author":"JM Kelly","year":"2017","unstructured":"Kelly JM, Amor-Coarasa A, Nikolopoulou A, W\u00fcstemann T, Barelli P, Kim D, et al. Dual-target binding ligands with modulated pharmacokinetics for endoradiotherapy of prostate cancer. J Nucl Med. 2017;58:1442\u20139.","journal-title":"J Nucl Med"},{"key":"979_CR49","first-page":"4025","volume":"63","author":"M-C Milot","year":"2022","unstructured":"Milot M-C, Benesty OB, Dumulon-Perreault V, Ait-Mohand S, Geha S, Richard P, et al. The journey to a novel theranostic for prostate cancer: the preclinical study of 64Cu-DOTHA2-PSMA. J Nucl Med. 2022;63:4025.","journal-title":"J Nucl Med"},{"key":"979_CR50","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00259-018-4220-z","volume":"46","author":"JC Dos Santos","year":"2019","unstructured":"Dos Santos JC, Sch\u00e4fer M, Bauder-W\u00fcst U, Lehnert W, Leotta K, Morgenstern A, et al. Development and dosimetry of 203Pb\/212Pb-labelled PSMA ligands: bringing \u201cthe lead\u201d into PSMA-targeted alpha therapy? Eur J Nucl Med Mol Imaging. 2019;46:1081\u201391.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"979_CR51","volume":"22","author":"VY Stenberg","year":"2021","unstructured":"Stenberg VY, Larsen RH, Ma LW, Peng Q, Juzenas P, Bruland \u00d8S, et al. Evaluation of the PSMA-binding ligand 212Pb-NG001 in multicellular tumour spheroid and mouse models of prostate cancer. Int J Mol Sci. 2021;22:4815.","journal-title":"Int J Mol Sci"},{"key":"979_CR52","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jlcr.3825","volume":"63","author":"VY Stenberg","year":"2020","unstructured":"Stenberg VY, Juzeniene A, Chen Q, Yang X, Bruland \u00d8S, Larsen RH. Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212Pb]Pb-NG001 for prostate cancer. J Labelled Comp Radiopharm. 2020;63:129\u201343.","journal-title":"J Labelled Comp Radiopharm"},{"key":"979_CR53","doi-asserted-by":"crossref","first-page":"980","DOI":"10.2967\/jnumed.120.256388","volume":"62","author":"SR Banerjee","year":"2021","unstructured":"Banerjee SR, Lisok A, Minn I, Josefsson A, Kumar V, Brummet M, et al. Preclinical evaluation of 213Bi- and 225Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer. J Nucl Med. 2021;62:980\u20138.","journal-title":"J Nucl Med"},{"key":"979_CR54","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2967\/jnumed.121.262098","volume":"63","author":"RC Mease","year":"2022","unstructured":"Mease RC, Kang CM, Kumar V, Banerjee SR, Minn I, Brummet M, et al. An improved 211At-labeled agent for PSMA-targeted \u03b1-therapy. J Nucl Med. 2022;63:259\u201367.","journal-title":"J Nucl Med"},{"key":"979_CR55","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00259-022-06016-z","volume":"50","author":"T Watabe","year":"2023","unstructured":"Watabe T, Kaneda-Nakashima K, Shirakami Y, Kadonaga Y, Ooe K, Wang Y, et al. Targeted \u03b1-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound. Eur J Nucl Med Mol Imaging. 2023;50:849\u201358.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"979_CR56","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00259-024-06945-x","volume":"52","author":"K Yaginuma","year":"2025","unstructured":"Yaginuma K, Takahashi K, Hoshi S, Joho T, Shimoyama S, Hasegawa N, et al. Novel astatine (211At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model. Eur J Nucl Med Mol Imaging. 2025;52:469\u201381.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"979_CR57","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2967\/jnumed.115.155929","volume":"56","author":"AP Kiess","year":"2015","unstructured":"Kiess AP, Minn I, Chen Y, Hobbs R, Sgouros G, Mease RC, et al. Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen. J Nucl Med. 2015;56:1401\u20137.","journal-title":"J Nucl Med"},{"key":"979_CR58","doi-asserted-by":"publisher","first-page":"18837","DOI":"10.1038\/s41598-023-43429-8","volume":"13","author":"C Baun","year":"2023","unstructured":"Baun C, Dam JH, Hildebrandt MG, Ewald JD, Kristensen BW, Gammelsr\u00f8d VS, et al. Preclinical evaluation of [58mCo]Co-DOTA-PSMA-617 for auger electron therapy of prostate cancer. Sci Rep. 2023;13:18837.","journal-title":"Sci Rep"},{"key":"979_CR59","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.2967\/jnumed.125.269751","volume":"66","author":"KN Bobba","year":"2025","unstructured":"Bobba KN, Wadhwa A, Bidkar AP, Raveendran A, Garcia L, Greenland N, et al. Evaluation of 134Ce\/134La-PSMA-617 for PET imaging and auger electron therapy of prostate cancer. J Nucl Med. 2025;66:1252\u20137.","journal-title":"J Nucl Med"},{"key":"979_CR60","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1053\/j.semnuclmed.2023.06.007","volume":"53","author":"S Alati","year":"2023","unstructured":"Alati S, Singh R, Pomper MG, Rowe SP, Banerjee SR. Preclinical development in radiopharmaceutical therapy for prostate cancer. Semin Nucl Med. 2023;53:663\u201386.","journal-title":"Semin Nucl Med"},{"key":"979_CR61","doi-asserted-by":"crossref","DOI":"10.3390\/ph15101292","volume":"15","author":"U Hennrich","year":"2022","unstructured":"Hennrich U, Eder M. [177Lu]Lu-PSMA-617 (pluvicto\u2122): the first FDA-approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals. 2022;15:1292.","journal-title":"Pharmaceuticals"},{"key":"979_CR62","volume":"15","author":"A Konopnicki","year":"2024","unstructured":"Konopnicki A, Zaliznyak M, Roy M, Jana B. The therapeutic use of 177Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials. Discover Oncol. 2024;15:791.","journal-title":"Discover Oncol"},{"key":"979_CR63","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13550-015-0114-2","volume":"5","author":"H Ahmadzadehfar","year":"2015","unstructured":"Ahmadzadehfar H, Rahbar K, K\u00fcrpig S, B\u00f6gemann M, Claesener M, Eppard E, et al. Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5:36.","journal-title":"EJNMMI Res"},{"key":"979_CR64","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/RLU.0000000000001240","volume":"41","author":"K Rahbar","year":"2016","unstructured":"Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L, et al. Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med. 2016;41:522\u20138.","journal-title":"Clin Nucl Med"},{"key":"979_CR65","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Sch\u00e4fers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85\u201390.","journal-title":"J Nucl Med"},{"key":"979_CR66","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825\u201333.","journal-title":"Lancet Oncol"},{"key":"979_CR67","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC. <article-title update=\"added\">[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804.","journal-title":"Lancet"},{"key":"979_CR68","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, De Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"979_CR69","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3390\/ph17020256","volume":"17","author":"KE de Roode","year":"2024","unstructured":"de Roode KE, Joosten L, Behe M. Towards the magic radioactive bullet: improving targeted radionuclide therapy by reducing the renal retention of radioligands. Pharmaceuticals. 2024;17:256.","journal-title":"Pharmaceuticals"},{"key":"979_CR70","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.7150\/thno.96403","volume":"14","author":"AP Bidkar","year":"2024","unstructured":"Bidkar AP, Zerefa L, Yadav S, VanBrocklin HF, Flavell RR. Actinium-225 targeted alpha particle therapy for prostate cancer. Theranostics. 2024;14:2969\u201392.","journal-title":"Theranostics"},{"key":"979_CR71","volume":"15","author":"J Ma","year":"2025","unstructured":"Ma J, Zhang Y, Yangqing J, Liu G, Wang J, Zhang C. The efficacy and safety of 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer. Front Oncol. 2025;15:1516860.","journal-title":"Front Oncol"},{"key":"979_CR72","doi-asserted-by":"crossref","first-page":"109032","DOI":"10.1016\/j.nucmedbio.2025.109032","volume":"146\u20137","author":"E Savio","year":"2025","unstructured":"Savio E, Reyes L, Giglio J, Alfaya L, Falasco G, Urrutia L, et al. Preclinical evaluation of [225Ac] ac-PSMA-617 and in vivo effect comparison in combination with [177Lu] Lu-PSMA-617 for prostate cancer. Nucl Med Biol. 2025;146\u20137:109032.","journal-title":"Nucl Med Biol"},{"key":"979_CR73","volume":"296","author":"L Wang","year":"2025","unstructured":"Wang L, Wang Xa, Wu D. PSMA targeted therapy: from molecular mechanisms to clinical breakthroughs in castration-resistant prostate cancer. Eur J Med Chem. 2025;296:117829.","journal-title":"Eur J Med Chem"},{"key":"979_CR74","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2967\/jnumed.120.246041","volume":"62","author":"J Czernin","year":"2021","unstructured":"Czernin J, Current K, Mona CE, Nyiranshuti L, Hikmat F, Radu CG, et al. Immune-checkpoint blockade enhances 225Ac-PSMA617 efficacy in a mouse model of prostate cancer. J Nucl Med. 2021;62:228\u201331.","journal-title":"J Nucl Med"}],"container-title":["Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13139-025-00979-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13139-025-00979-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13139-025-00979-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T09:59:52Z","timestamp":1791626392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13139-025-00979-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["979"],"URL":"https:\/\/doi.org\/10.1007\/s13139-025-00979-1","relation":{},"ISSN":["1869-3474","1869-3482"],"issn-type":[{"value":"1869-3474","type":"print"},{"value":"1869-3482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Muzammal Ayman, Kyo Chul Lee, and Sairan Eom declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Human Ethics and Consent to Participate declarations","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the authors used ChatGPT (OpenAI) to check grammar and enhance readability of some sentences. After using this tool, the authors carefully reviewed and edited the content as necessary and take full responsibility for the final content of the publication.","order":5,"name":"Ethics","label":"Declaration of Generative AI in Scientific Writing","group":{"name":"EthicsHeading","label":"Declarations"}}]}}